Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation

Abstract

Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.

1 . A method for delivering an anti-BAFFR antibody to a mammal, comprising administering to said mammal an aqueous composition having a pH of 5.0-7.0 and comprising
 (i) an anti-BAFFR antibody wherein the antibody has a concentration of 18-165 mg/mL, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,   (ii) a stabilizer,   (iii) a buffering agent,   (iv) a surfactant, and, optionally,   (v) an amino acid.   
     
     
         2 . The method of  claim 1 , wherein the patient has a disease or disorder mediated by BAFF receptor. 
     
     
         3 . The method of  claim 1 , wherein the patient has a B cell neoplasm. 
     
     
         4 . The method of  claim 3 , wherein the B cell neoplasm is lymphoma, leukemia or myeloma. 
     
     
         5 . A method of killing or depleting B cells in a mammal, comprising administering to said mammal an aqueous composition having a pH of 5.0-7.0 and comprising
 (i) an anti-BAFFR antibody wherein the antibody has a concentration of 18-165 mg/mL, and wherein said anti-BAFFR antibody includes heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs: 6, 7 and 8,   (ii) a stabilizer,   (iii) a buffering agent,   (iv) a surfactant, and, optionally,   (v) an amino acid.   
     
     
         6 . The method of  claim 5 , wherein the mammal is human.